<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T05:12:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3654748" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:3654748</identifier>
        <datestamp>2013-05-17</datestamp>
        <setSpec>jid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Infect. Dis</journal-id>
              <journal-id journal-id-type="publisher-id">jid</journal-id>
              <journal-id journal-id-type="hwp">jinfdis</journal-id>
              <journal-title-group>
                <journal-title>The Journal of Infectious Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0022-1899</issn>
              <issn pub-type="epub">1537-6613</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC3654748</article-id>
              <article-id pub-id-type="pmcid">PMC3654748</article-id>
              <article-id pub-id-type="pmc-uid">3654748</article-id>
              <article-id pub-id-type="pmid">23493728</article-id>
              <article-id pub-id-type="pmid">23493728</article-id>
              <article-id pub-id-type="doi">10.1093/infdis/jit099</article-id>
              <article-id pub-id-type="publisher-id">jit099</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Major Articles and Brief Reports</subject>
                  <subj-group subj-group-type="heading">
                    <subject>HIV/AIDS</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The Phenotype of the <italic>Cryptococcus</italic>-Specific
CD4<sup>+</sup> Memory T-Cell Response Is Associated With Disease Severity and
Outcome in HIV-Associated Cryptococcal Meningitis</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jarvis</surname>
                    <given-names>Joseph N.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af1">1</xref>
                  <xref ref-type="aff" rid="af2">2</xref>
                  <xref ref-type="aff" rid="af4">4</xref>
                  <xref ref-type="aff" rid="af5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Casazza</surname>
                    <given-names>Joseph P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stone</surname>
                    <given-names>Hunter H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meintjes</surname>
                    <given-names>Graeme</given-names>
                  </name>
                  <xref ref-type="aff" rid="af5">5</xref>
                  <xref ref-type="aff" rid="af6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lawn</surname>
                    <given-names>Stephen D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levitz</surname>
                    <given-names>Stuart M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harrison</surname>
                    <given-names>Thomas S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af1">1</xref>
                  <xref ref-type="author-notes" rid="AN1">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Koup</surname>
                    <given-names>Richard A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="af7">7</xref>
                  <xref ref-type="author-notes" rid="AN1">a</xref>
                </contrib>
              </contrib-group>
              <aff id="af1"><label>1</label><addr-line>Research Centre for Infection and Immunity, Division
of Clinical Sciences</addr-line>, <institution>St. George's University of
London</institution></aff>
              <aff id="af2"><label>2</label><addr-line>Department of Clinical Research, Faculty of
Infectious and Tropical Diseases</addr-line>, <institution>London School of Hygiene and
Tropical Medicine</institution></aff>
              <aff><label>3</label><addr-line>Department of Medicine</addr-line>, <institution>Imperial
College London</institution>, <country>United Kingdom</country></aff>
              <aff id="af4">
                <label>4</label>
                <addr-line>Desmond Tutu HIV Centre</addr-line>
              </aff>
              <aff id="af5">
                <label>5</label>
                <addr-line>Institute of Infectious Disease and Molecular Medicine</addr-line>
              </aff>
              <aff id="af6"><label>6</label><addr-line>Department of Medicine</addr-line>,
<institution>University of Cape Town</institution>, <country>South Africa</country></aff>
              <aff id="af7"><label>7</label><addr-line>Immunology Laboratory, Vaccine Research
Center</addr-line>, <institution>National Institute of Allergy and Infectious Diseases,
National Institutes of Health</institution>, <addr-line>Bethesda,
Maryland</addr-line></aff>
              <aff id="af8"><label>8</label><addr-line>Department of Medicine</addr-line>,
<institution>University of Massachusetts Medical School</institution>,
<addr-line>Worcester</addr-line></aff>
              <author-notes>
                <fn fn-type="con" id="AN1">
                  <label>a</label>
                  <p>T. S. H. and R. A. K. contributed equally to this article.</p>
                </fn>
                <corresp>Correspondence: Joseph N. Jarvis, MBBS, MRCP, DTM&amp;H, PhD, Department of
Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene
and Tropical Medicine, Keppel Street, London, WC1E 7HT
(<email>joejarvis@doctors.net.uk</email>).</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>15</day>
                <month>6</month>
                <year>2013</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>3</month>
                <year>2013</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>3</month>
                <year>2013</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
              <volume>207</volume>
              <issue>12</issue>
              <fpage>1817</fpage>
              <lpage>1828</lpage>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>8</month>
                  <year>2012</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>12</month>
                  <year>2012</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author 2013. Published by Oxford University Press on behalf
of the Infectious Diseases Society of America.</copyright-statement>
                <copyright-year>2013</copyright-year>
                <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs licence (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</uri>), which permits
non-commercial reproduction and distribution of the work, in any medium, provided the
original work is not altered or transformed in any way, and that the work properly
cited. For commercial re-use, please contact
<email>journals.permissions@oup.com</email>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="jit099.pdf"/>
              <abstract>
                <p><bold><italic>Background.</italic></bold>âCorrelates of immune protection in
patients with human immunodeficiency virus (HIV)âassociated cryptococcal meningitis
are poorly defined. A clearer understanding of these immune responses is essential to
inform rational development of immunotherapies.</p>
                <p><bold><italic>Methods.</italic></bold>âCryptococcal-specific peripheral
CD4<sup>+</sup> T-cell responses were measured in 44 patients with HIV-associated
cryptococcal meningitis at baseline and during follow-up. Responses were assessed
following ex vivo cryptococcal mannoprotein stimulation, using 13-color flow-cytometry.
The relationships between cryptococcal-specific CD4<sup>+</sup> T-cell responses,
clinical parameters at presentation, and outcome were investigated.</p>
                <p><bold><italic>Results.</italic></bold>âCryptococcal-specific CD4<sup>+</sup>
T-cell responses were characterized by the production of macrophage inflammatory protein
1Î±, interferon Î³ (IFN-Î³), and tumor necrosis factor Î± (TNF-Î±).
Conversely, minimal interleukin 4 and interleukin 17 production was detected. Patients
surviving to 2 weeks had significantly different functional CD4<sup>+</sup> T-cell
responses as compared to those who died. Patients with a response predominantly consisting
of IFN-Î³ or TNF-Î± production had a 2-week mortality of 0% (0/20), compared
with 25% (6/24) in those without this response (<italic>P</italic> = .025).
Such patients also had lower fungal burdens (10 400 vs 390 000 colony-forming units/mL;
<italic>P</italic> &lt; .001), higher cerebrospinal fluid lymphocyte counts (122 vs 8
cells/Î¼L; <italic>P</italic> &lt; .001), and a trend toward faster rates of clearance
of infection.</p>
                <p><bold><italic>Conclusions.</italic></bold>âThe phenotype of the peripheral
CD4<sup>+</sup> T-cell response to <italic>Cryptococcus</italic> was associated
with disease severity and outcome in HIV-associated cryptococcal meningitis.
IFN-Î³/TNF-Î±âpredominant responses were associated with survival.</p>
              </abstract>
              <kwd-group>
                <kwd>HIV</kwd>
                <kwd>cryptococcus neoformans</kwd>
                <kwd>TB</kwd>
                <kwd>CMV</kwd>
                <kwd>memory T cells</kwd>
                <kwd>flow cytometry</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <p>
              <bold>(See the editorial commentary by Williamson on pages 1793â5.)</bold>
            </p>
            <p>Cryptococcal meningitis is a leading cause of mortality in human immunodeficiency virus
(HIV)âinfected patients in the developing world [<xref ref-type="bibr" rid="JIT099C1">1</xref>]. A clear understanding of the underlying immune response to
<italic>Cryptococcus neoformans</italic> is essential to help elucidate the causes of
mortality and inform development of immune-based therapies. Unfortunately, correlates of
immune protection in patients with HIV-associated cryptococcal meningitis remain poorly
defined.</p>
            <p>Most data regarding the immune response to <italic>C. neoformans</italic> comes from animal
models and in vitro work. <italic>Cryptococcus</italic> evades killing by the innate immune
system [<xref ref-type="bibr" rid="JIT099C2">2</xref>], and adaptive CD4<sup>+</sup>
T-cell responses are critical for immune control and clearance [<xref ref-type="bibr" rid="JIT099C3">3</xref>â<xref ref-type="bibr" rid="JIT099C6">6</xref>]. In mouse
models, a dichotomy exists between T-helper 1 (Th1)âtype T-cell responses and T-helper
2 (Th2)âtype responses. Th1-type responses are protective and associated with
proinflammatory cytokine responses; production of interferon Î³ (IFN-Î³), tumor
necrosis factor Î± (TNF-Î±), and interleukin 12; and effective intracellular killing
of <italic>C. neoformans</italic> by classically activated macrophages [<xref ref-type="bibr" rid="JIT099C3">3</xref>, <xref ref-type="bibr" rid="JIT099C4">4</xref>,
<xref ref-type="bibr" rid="JIT099C7">7</xref>â<xref ref-type="bibr" rid="JIT099C20">20</xref>]. Th2-type responses appear to be detrimental and are characterized by
production of interleukin 10 (IL-10), interleukin 4 (IL-4), and interleukin 13; alternative
macrophage activation; increased <italic>C. neoformans</italic> proliferation; and impaired
killing by innate effector cells [<xref ref-type="bibr" rid="JIT099C7">7</xref>, <xref ref-type="bibr" rid="JIT099C16">16</xref>â<xref ref-type="bibr" rid="JIT099C28">28</xref>]. T-helper 17 (Th17)âtype cytokine production has also been associated
with reduced fungal burdens and effective resolution of infection [<xref ref-type="bibr" rid="JIT099C29">29</xref>â<xref ref-type="bibr" rid="JIT099C32">32</xref>].</p>
            <p>Human data are limited. The epidemiology of cryptococcal disease clearly demonstrates that
CD4<sup>+</sup> T-cell depletion is the key predisposing factor [<xref ref-type="bibr" rid="JIT099C33">33</xref>]. Cryptococcal meningitis nearly exclusively
affects patients with profound defects in cell-mediated immunity. In HIV-infected patients
who develop cryptococcal meningitis, adverse clinical and microbiological outcomes are
associated with lower CD4<sup>+</sup> T-cell counts and poor inflammatory responses in
the cerebrospinal fluid (CSF) [<xref ref-type="bibr" rid="JIT099C34">34</xref>â<xref ref-type="bibr" rid="JIT099C36">36</xref>], but the phenotype of the immune response in
HIV-infected patients with cryptococcal meningitis is not well described. HIV disease
progression has been associated with a loss of Th1-type responses and a switch to
Th2-weighted CD4<sup>+</sup> T-cell and cytokine responses [<xref ref-type="bibr" rid="JIT099C37">37</xref>â<xref ref-type="bibr" rid="JIT099C39">39</xref>], although
very few data are available that directly examine the functional phenotypes of
CD4<sup>+</sup> T cells in HIV-infected patients with advanced disease.</p>
            <p>To explore the host response to cryptococcal infection in patients with HIV-associated
cryptococcal meningitis, both at the site of infection in the central nervous system and
systemically, CSF cytokine levels and <italic>Cryptococcus-</italic>specific peripheral
CD4<sup>+</sup> T-cell responses were measured in an exploratory analysis of 44
patients with acute cryptococcal meningitis enrolled in a trial of adjuvant interferon gamma
immunotherapy. The phenotype of the peripheral CD4<sup>+</sup> T-cell responses to
<italic>Cryptococcus</italic> was compared to better characterized antigen-specific
cytomegalovirus (CMV)â and <italic>Mycobacterium tuberculosis</italic>âspecific
responses [<xref ref-type="bibr" rid="JIT099C40">40</xref>, <xref ref-type="bibr" rid="JIT099C41">41</xref>], both to act as internal validation of the performance of the
experiments and to enable a comparison between the CD4<sup>+</sup> T-cell responses to
mycobacterial, fungal, and viral opportunistic infections. The relationships between
<italic>Cryptococcus-</italic>specific peripheral CD4<sup>+</sup> T-cell responses
and clinical parameters and outcomes were explored.</p>
            <sec sec-type="methods" id="s2">
              <title>METHODS</title>
              <sec id="s2a">
                <title>Study Subjects</title>
                <p>Subjects were participants in a randomized controlled trial examining the effect of
short-course adjuvant interferon gamma immunotherapy for the treatment of HIV-associated
cryptococcal meningitis. The trial was performed in Cape Town, South Africa, between 2007
and 2010 and has been described elsewhere (<ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jit099/-/DC1">Supplementary Methods</ext-link>) [<xref ref-type="bibr" rid="JIT099C42">42</xref>].
Written informed consent was obtained. The study was approved by the research ethics
committees of the University of Cape Town and St. George's University of London.</p>
              </sec>
              <sec id="s2b">
                <title>CSF Cytokine Analysis</title>
                <p>CSF samples were collected at baseline, prior to receipt of antifungal therapy, and
centrifuged, and the supernatant was frozen at â80Â°C for subsequent
quantification of cytokine concentrations. Levels of interleukin 2 (IL-2), IL-4,
interleukin 6 (IL-6), IL-10, interleukin 17 (IL-17), IFN-Î³, TNF-Î±, RANTES,
macrophage inflammatory protein 1Î± (MIP-1Î±), monocyte chemotactic protein 1
(MCP-1), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured using
Luminex multiplex cytokine analysis (Bio-plex kits, Bio-Rad Laboratories).</p>
              </sec>
              <sec id="s2c">
                <title>Peripheral Blood Mononuclear Cell (PBMC) Flow Cytometry Analysis</title>
                <p>PBMCs were obtained from 30 mL of venous blood taken at study admission (prior to any
therapy), study day 14, and after 1 month of antiretroviral therapy (ART). Cryptococcal
antigen (CRAG) stimulations were performed using purified cryptococcal mannoproteins
[<xref ref-type="bibr" rid="JIT099C43">43</xref>]. CMV stimulations were performed using
pp65 peptides, and <italic>M. tuberculosis</italic> stimulations were performed using a
mix of purified protein derivative, ESAT-6, and CFP-10. Cell stimulation and staining were
performed using a modification of the method described by Betts et al [<xref ref-type="bibr" rid="JIT099C44">44</xref>]. Cells were analyzed using a modified LSRII
(BD Immunocytometry Systems). Analytic gating of the flow cytometry data was performed
using FlowJo (version 9.0.1; TreeStar). For polychromatic analysis, all
CD4<sup>+</sup> T cells were identified in the same manner, and standard cytokine
gates were applied to all samples. The memory T-cell population was defined as
CD3<sup>+</sup>CD8<sup>â</sup>CD4<sup>+</sup> cells that were not
CD27<sup>+</sup>CD45RO<sup>â</sup>. Cytokine gating for IFN-Î³, IL-2,
IL-4, IL-17, MIP-1Î±, and TNF-Î± was done on the memory-cell population (<ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jit099/-/DC1">Supplementary Methods</ext-link> and Figure <xref ref-type="fig" rid="JIT099F1">1</xref>). <fig id="JIT099F1" position="float"><label>Figure 1.</label><caption><p><italic>A,</italic> Analytic gating of the flow cytometry data.
<italic>a</italic>, Singlet cells were sorted from aggregates on the basis of
forward-scatter height (FSC-H) and forward-scatter area (FSC-A). <italic>b</italic>,
Dead cells, B-cells, and monocytes were excluded by staining with live/dead violet
viability/vitality dye staining and CD14 and CD19 staining. <italic>c</italic>, The
small lymphocyte population was selected. <italic>d</italic>, CD3<sup>+</sup>
cells were selected. CD3<sup>+</sup>CD8<sup>â</sup> cells
(<italic>e</italic>) and then CD3<sup>+</sup>CD4<sup>+</sup> cells
(<italic>f</italic>) were sequentially selected. <italic>g</italic>, The memory
T-cell population was defined as
CD3<sup>+</sup>CD8<sup>â</sup>CD4<sup>+</sup> cells that were not
CD27<sup>+</sup>CD45RO<sup>â</sup>. <italic>h</italic>, Cytokine gating
for interferon Î³ (IFN-Î³), interleukin 2 (IL-2), interleukin 4 (IL-4),
interleukin 17 (IL-17), macrophage inflammatory protein 1Î± (MIP-1Î±) and
tumor necrosis factor Î± (TNF-Î±) was done on the memory cell population.
<italic>B</italic>, Analytic gating of the flow cytometry data is shown. Cytokine
gating for IFN-Î³, IL-2, IL-4, IL-17, MIP-1Î±, and TNF-Î± was done on the
memory cell population.</p></caption><graphic xlink:href="jit09901"/></fig></p>
              </sec>
              <sec id="s2d">
                <title>Statistical Analysis</title>
                <p>Data were analyzed using Stata, version 11.0 (StataCorp); Prism, version 5a (GraphPad
Software); and Spice, version 5.2 (NIAID, NIH, Bethesda, MD). Variables were compared
across groups, using the MannâWhitney <italic>U</italic>, KruskalâWallis,
Ï<sup>2</sup>, or Fisher exact tests. Comparisons of paired groups were made using
the Wilcoxon matched pairs test. The Spearman correlation coefficient was used to examine
associations between continuous variables, and an adjusted linear regression model
compared early fungicidal activity by treatment group. Patterns of cytokine production
between response phenotypes were compared by permutation analysis, using a 1 000
000-iteration Monte Carlo simulation model described in detail elsewhere [<xref ref-type="bibr" rid="JIT099C45">45</xref>]. Because this was an exploratory study to
highlight potentially novel findings and avenues for future research, adjustment for
multiple comparisons was not made, because use of stringent adjustment markedly increases
the probability of type 2 errors. For all analyses, the 2-dose and 6-dose IFN-Î³
treatment groups were considered as a single âIFN-Î³âtreatedâ group.
Statistical significance was defined as <italic>P</italic> value of â¤ .05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>RESULTS</title>
              <p>PBMCs were collected from 44 HIV-infected patients at presentation with cryptococcal
meningitis. The median age was 32 years, 43% were male, and the median
CD4<sup>+</sup> T-cell count was 24 cells/Î¼L (Table <xref ref-type="table" rid="JIT099TB1">1</xref>). Eighteen patients received standard antifungal therapy, and 26
received standard therapy plus interferon gamma. Two-week mortality was 14%. For
patients who survived, ART was initiated after a median of 23 days of antifungal therapy.
None of the patients had clinically apparent CMV disease at the time of sample collection or
developed CMV end-organ disease during the first year of ART. Thirty-four percent of
patients (15) were being treated for tuberculosis at the time of sample collection, a
further 23% (10) had a history of treated tuberculosis, and 5% (2) developed
tuberculosis during the 1-year follow-up period. Additional PBMC samples were collected from
37 of the 38 surviving patients 2 weeks after the initial sample was collected, following
completion of induction-phase antifungal therapy but prior to ART initiation, and from 16
surviving patients 1 month following ART initiation. <table-wrap id="JIT099TB1" position="float"><label>Table 1.</label><caption><p>Baseline Characteristics of the Cohort</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Overall</th><th align="left" rowspan="1" colspan="1">Alive at 2 wk</th><th align="left" rowspan="1" colspan="1">Died at 2 wk</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, y</td><td rowspan="1" colspan="1">32 (28â38)</td><td rowspan="1" colspan="1">32 (27â38)</td><td rowspan="1" colspan="1">32 (28â34)</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">43 (19)</td><td rowspan="1" colspan="1">45 (17)</td><td rowspan="1" colspan="1">33 (2)</td></tr><tr><td rowspan="1" colspan="1">CD4<sup>+</sup> T-cell count, cells/Î¼L</td><td rowspan="1" colspan="1">24 (15â50)</td><td rowspan="1" colspan="1">26 (16â63)</td><td rowspan="1" colspan="1">15 (9â39)</td></tr><tr><td rowspan="1" colspan="1">HIV load, log<sub>10</sub> copies/mL</td><td rowspan="1" colspan="1">4.99 (4.4â5.4)</td><td rowspan="1" colspan="1">4.94 (4.4â5.4)</td><td rowspan="1" colspan="1">5.32 (5.0â5.7)</td></tr><tr><td rowspan="1" colspan="1">CSF lymphocyte count, Ã10<sup>6</sup> cells/L</td><td rowspan="1" colspan="1">15 (1â60)</td><td rowspan="1" colspan="1">23 (1â100)</td><td rowspan="1" colspan="1">2 (0â5)</td></tr><tr><td rowspan="1" colspan="1">Baseline fungal burden, log<sub>10</sub> CFU/mL</td><td rowspan="1" colspan="1">5.29 (4.0â5.9)</td><td rowspan="1" colspan="1">5.27 (4.0â5.8)</td><td rowspan="1" colspan="1">5.9 (3.3â6.1)</td></tr><tr><td rowspan="1" colspan="1">Abnormal mental status</td><td rowspan="1" colspan="1">34 (15)</td><td rowspan="1" colspan="1">32 (12)</td><td rowspan="1" colspan="1">50 (3)</td></tr><tr><td rowspan="1" colspan="1">2-wk mortality</td><td rowspan="1" colspan="1">14 (6)</td><td rowspan="1" colspan="1">â¦</td><td rowspan="1" colspan="1">â¦</td></tr></tbody></table><table-wrap-foot><fn><p>Data are median (interquartile range) or % (no.) of subjects.</p></fn><fn><p>Abbreviations: CFU, colony-forming units; CSF, cerebrospinal fluid; HIV, human
immunodeficiency virus.</p></fn></table-wrap-foot></table-wrap></p>
              <sec id="s3a">
                <title>Frequency and Magnitude of Antigen-Specific CD4<sup>+</sup> T-Cell
Responses</title>
                <p>At baseline, CRAG-specific memory CD4<sup>+</sup> T-cell responses were present in
70% of patients (31/44), CMV-specific responses were present in 77% (20/26),
and <italic>M. tuberculosis</italic>âspecific responses were present in 68%
(13/19). The median frequencies of CRAG-, CMV- and <italic>M.
tuberculosis</italic>âspecific memory CD4<sup>+</sup> T cells in patients with
detectable responses were 0.86% (interquartile range [IQR],
0.5%â1.6%), 0.29% (IQR, 0.15%â1.1%), and
1.34% (IQR, 0.6%â2.3%), respectively (Figure <xref ref-type="fig" rid="JIT099F2">2</xref><italic>A</italic>). Despite no clinical evidence
of CMV disease, a number of patients had extremely large CMV-specific responses: in one
patient, 85% of memory CD4<sup>+</sup> T cells were CMV specific. <italic>M.
tuberculosis</italic>âspecific responses were present in 100% of patients
(4/4) with active tuberculosis, 75% (3/4) with previous tuberculosis, and
55% (6/11) with no history of tuberculosis, none of whom developed active
tuberculosis during the 1-year follow-up period. <fig id="JIT099F2" position="float"><label>Figure
2.</label><caption><p><italic>A</italic>, The magnitude of cryptococcal antigen (CRAG)â,
cytomegalovirus (CMV)â, and <italic>Mycobacterium
tuberculosis</italic>âspecific CD4<sup>+</sup> T-cell responses in
patients with HIV-associated cryptococcal meningitis. The frequency of CRAG-, CMV-,
and <italic>M. tuberculosis</italic>âspecific CD4<sup>+</sup> memory
T-cell responses in patients with a detectable antigen-specific response at baseline
is shown. The frequency of cytokine-producing cells in each individual is shown as a
percentage of their total memory CD4<sup>+</sup> T-cell population. Wide bars
represent the median percentage, with error bars showing the interquartile range. A
detectable total CD4<sup>+</sup> T-cell response was defined as at least
0.1% of cells cytokine positive after subtraction of background, with at
least 10 cytokine-positive events over background. Statistical comparison between
groups was performed using the Kruskal-Wallis test. In the 4 patients with large
magnitude CMV responses, 10%, 18%, 23%, and 85% of
CD4<sup>+</sup> memory T cells were CMV specific. In the 2 patients with
large-magnitude <italic>M. tuberculosis</italic> responses, 6% and 7%
of CD4<sup>+</sup> memory T cells were <italic>M. tuberculosis</italic>
specific. <italic>B</italic>, Differences in cytokine production in response to
CRAG, CMV, and <italic>M. tuberculosis</italic>. The proportion of CRAG-, CMV-, and
<italic>M. tuberculosis</italic>âspecific CD4<sup>+</sup> memory T
cells producing interferon Î³ (IFN-Î³), interleukin 2 (IL-2), interleukin 4
(IL-4), interleukin 17 (IL-17), macrophage inflammatory protein 1Î± (MIP-1Î±),
and tumor necrosis factor Î± (TNF-Î±; as determined by flow cytometry after
background subtraction) in patients with a detectable antigen specific response is
shown. Bars are to the median, with error bars to the 75th percentile. The
proportion of IFN-Î³âproducing cells was highest in the CMV-specific
responses, while <italic>M. tuberculosis</italic>âspecific responses had the
highest proportions of IL-2 and TNF-Î± production, and MIP-1Î± production was
highest in CRAG-specific responses.</p></caption><graphic xlink:href="jit09902"/></fig></p>
              </sec>
              <sec id="s3b">
                <title>Phenotype of Response</title>
                <p>Maturational and functional characteristics were examined in pathogen-specific
CD4<sup>+</sup> T cells at baseline. Cellular maturation was studied using the
differentiation markers CD27, CD45RO, and CD57 to distinguish between naive
(CD27<sup>+</sup>CD45RO<sup>â</sup>), CD27<sup>+</sup> memory
(CD27<sup>+</sup>CD45RO<sup>+</sup>), effector-memory
(CD27<sup>â</sup>CD45RO<sup>+</sup>), and terminally differentiated
(CD57<sup>+</sup>) CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="JIT099C46">46</xref>]. <italic>M. tuberculosis</italic>âspecific
CD4<sup>+</sup> T cells had the least mature functional profile, with 18%
having a CD27<sup>+</sup> memory phenotype, 75% having an effector-memory
phenotype, and 7% having a terminally differentiated phenotype. Of the
CRAG-specific CD4<sup>+</sup> T cells, 13% had a CD27<sup>+</sup> memory
phenotype, 67% had an effector-memory phenotype, and 18% had a terminally
differentiated phenotype. CMV-specific CD4<sup>+</sup> T cells had the most mature
phenotype, with 14% having a CD27<sup>+</sup> memory phenotype, 33%
having an effector-memory phenotype, and 53% having a terminally differentiated
phenotype.</p>
                <p>To further assess baseline functional response, expression of IL-2, IL-4, IL-17,
MIP-1Î±, IFN-Î³, and TNF-Î± was measured. Significantly different patterns of
cytokine production were detected in the CRAG-, CMV- and <italic>M.
tuberculosis</italic>âspecific T-cell responses (Figure <xref ref-type="fig" rid="JIT099F2">2</xref><italic>B</italic>). A large proportion of CRAG-specific
CD4<sup>+</sup> T cells produced MIP-1Î± (median, 65%), with slightly
less IFN-Î³ and TNF-Î± production (median, 37% and 28%, respectively).
Negligible IL-2, IL-4, and IL-17 production was observed. In contrast, CMV-specific T
cells primarily produced IFN-Î³ (median, 75%) and TNF-Î± (median,
53%), with lower proportions of MIP-1Î± (median, 34%) and IL-2 (median,
11%). <italic>M. tuberculosis</italic>âspecific responses were characterized
by a very high percentage of TNF-Î±âproducing cells (median, 90%), along
with a lower proportion of IFN-Î³â (median, 9%), MIP-1Î±â, and
IL-2âproducing cells. Very little antigen-specific IL-4 or IL-17 production was
detected with either CMV or <italic>M. tuberculosis</italic> stimulation.</p>
                <p>Baseline polyfunctional phenotypes were assessed throughout the 64 different possible
combinations of the 6 cytokines (data not shown); however, as IL-4 and IL-17 production
was minimal, phenotypic analysis of a 4-function panel (IFN-Î³, IL-2, MIP-1Î±, and
TNF-Î±) yielded results that were comparable to those for the full 6-function panel. In
keeping with the overall cytokine production presented above, significantly differing
functional phenotypes were seen in the different antigen-specific T-cell responses (CRAG
vs CMV, <italic>P</italic> &lt; .001; CRAG vs <italic>M. tuberculosis</italic>,
<italic>P</italic> = .03; Figure <xref ref-type="fig" rid="JIT099F3">3</xref>).
CRAG-specific responses were characterized by a predominance of single-function
MIP-1Î±âproducing cells (median, 42%; IQR, 23%â77%),
with single-function IFN-Î³âproducing cells (median, 6%; IQR,
1%â11%) and single-function TNF-Î±âproducing cells (median,
4%; IQR, 0%â15%) the next most frequent phenotypes. Very little
polyfunctionality was observed, with a relatively small proportion of dual-function cells
producing TNF-Î± and IFN-Î³ (median, 4%; IQR, 0%â15%) and
a very low proportion of cells producing any other combination of â¥2 cytokines. In
contrast, CMV-specific responses were characterized by a notable proportion of
triple-function cells producing either TNF-Î±, IFN-Î³, and MIP-1Î± (median,
10%; IQR, 1%â27%) or TNF-Î±, IFN-Î³, and IL-2 (median,
6%; IQR, 2â12), along with a large proportion of dual-function cells
producing TNF-Î± and IFN-Î³ (median, 16%; IQR, 6%â17%).
<italic>M. tuberculosis</italic>âspecific responses were less polyfunctional and
were characterized by large proportions of single-function TNF-Î±âproducing cells
(median, 34%; IQR, 15%â49%). <fig id="JIT099F3" position="float"><label>Figure
3.</label><caption><p>The functional phenotype of cryptococcal antigen (CRAG)â,
cytomegalovirus (CMV)â, and <italic>Mycobacterium
tuberculosis</italic>âspecific CD4<sup>+</sup> memory T-cell responses at
baseline. Peripheral blood mononuclear cells from human immunodeficiency
virusâpositive subjects with cryptococcal meningitis were stimulated with
cryptococcal mannoprotein, CMV pp65, or <italic>M. tuberculosis</italic> ESAT-6,
CFP-10, and PPD. Flow cytometry of interferon Î³ (IFN-Î³), interleukin 2
(IL-2), macrophage inflammatory protein 1Î± (MIP-1Î±), and tumor necrosis
factor Î± (TNF-Î±) production within pathogen-specific CD4<sup>+</sup>
memory T cells is shown. The bar chart shows each of the 15 possible response
profiles on the <italic>x</italic>-axis. The percentage of the total cytokine
response is shown on the <italic>y</italic>-axis, with the filled bar representing
the interquartile range and a line at the median. CRAG-specific responses are shown
in blue, CMV-specific responses are in red, and <italic>M.
tuberculosis</italic>âspecific responses are in green. Statistically
significant differences (<italic>P</italic> &lt; .05) by rank-sum testing are
indicated by the pound sign. The pie charts show the fractions according to the
pie-slice colors shown at the bottom of the bar chart, with color-coded circles
indicating the contributions of IFN-Î³ (red), IL-2 (yellow), MIP-1Î± (green),
and TNF-Î± (blue) to the 4-, 3-, 2-, and 1-function responses. Statistical
comparisons of the overall responses by permutation testing are shown in the pie
category test result chart.</p></caption><graphic xlink:href="jit09903"/></fig></p>
              </sec>
              <sec id="s3c">
                <title>Temporal Changes in Response</title>
                <p>Between baseline and day 14, there were no significant changes in the magnitude or
phenotype of antigen-specific T-cell responses to CRAG, CMV, or <italic>M.
tuberculosis</italic>. Following 1 month of ART, there was no significant change in the
overall median frequency of CRAG-specific CD4<sup>+</sup> T cells, but significant
decreases of 90% in the frequency of IFN-Î³âproducing cells
(<italic>P</italic> = .03) and 49% in the frequency of
TNF-Î±âproducing cells (<italic>P</italic> = .02) were observed.
Conversely, there was an increase of 49% in the frequency of CMV-specific T cells
(<italic>P</italic> = .09), which was primarily accounted for by an increase in
the frequency of IFN-Î³âproducing cells. There was also a very large increase of
&gt;10-fold (1116%) in the frequency of IFN-Î³âproducing <italic>M.
tuberculosis</italic>âspecific T cells following 1 month of ART
(<italic>P</italic> = .03), along with a 98% increase in frequency of
TNF-Î±âproducing <italic>M. tuberculosis</italic>âspecific T cells
(<italic>P</italic> = .03), the same pattern seen both in those with and those
without active tuberculosis.</p>
              </sec>
              <sec id="s3d">
                <title>Associations Between CRAG-Specific T-Cell Responses and Clinical Presentation and
Outcome of Cryptococcal Meningitis</title>
                <p>Associations between the CRAG-specific T-cell responses and the baseline fungal burden,
rate of clearance of infection, and mortality at 2 weeks were first examined according to
the presence or absence of a detectable antigen-specific response (hereafter referred to
as âtotal responseâ). There were no significant differences in either baseline
fungal burden or rate of clearance of infection in patients with and patients without
CRAG-specific T-cell responses, and mortality in the 2 groups was similar (13% vs
15%; <italic>P</italic> = 1.0). However, the functional phenotype of the
response differed significantly between those who survived and those who died
(<italic>P</italic> = .01; Figure <xref ref-type="fig" rid="JIT099F4">4</xref>).
Those who died had a significantly higher proportion of single-function
MIP-1Î±âproducing cells than those who survived (80% vs 38%;
<italic>P</italic> = .02). Survivors tended to have higher percentages of
single-function IFN-Î³-producing cells (7% vs 0%; <italic>P</italic>
= .19) and single-function TNF-Î±âproducing cells (6% vs 1%;
<italic>P</italic> = .13) and a larger proportion of polyfunctional dual-function
IFN-Î³â plus TNF-Î±âproducing cells (7% vs 0%;
<italic>P</italic> = .35) than those who died. <fig id="JIT099F4" position="float"><label>Figure
4.</label><caption><p>Differences in functional phenotype of the cryptococcal antigen
(CRAG)âspecific responses at baseline between subjects who survived and
subjects who died. Results of flow cytometry of interferon Î³ (IFN-Î³),
interleukin 2 (IL-2), macrophage inflammatory protein 1Î± (MIP-1Î±), and tumor
necrosis factor Î± (TNF-Î±) production within CRAG-specific
CD4<sup>+</sup> memory T cells at baseline for patients who survived to 2
weeks and those who died are shown. The bar chart shows each of the 15 possible
response profiles on the <italic>x</italic>-axis. The percentage of the total
cytokine response is shown on the <italic>y</italic>-axis, with the filled bar
representing the interquartile range and a line at the median. CRAG-specific
responses in survivors are shown in blue, and response for those who died are in
red. Statistically significant differences (<italic>P</italic> &lt; .05) on rank-sum
testing are indicated by the pound sign. The pie charts show the fractions according
to the pie-slice colors shown at the bottom of the bar chart, with color-coded
circles indicating the contributions of IFN-Î³ (red), IL-2 (yellow), MIP-1Î±
(green), and TNF-Î± (blue) to the 4-, 3-, 2-, and 1-function responses.
Statistical comparisons of the overall responses in those who survived versus those
who died by permutation testing are shown in the pie category test result
chart.</p></caption><graphic xlink:href="jit09904"/></fig></p>
                <p>To further examine associations between the antigen-specific CD4<sup>+</sup> T-cell
response phenotype and clinical outcome, the absolute numbers of CRAG-specific T cells
(ie, total response) and IFN-Î³â, TNF-Î±â, and
MIP-1Î±âproducing T cells were calculated according to mortality (Figure <xref ref-type="fig" rid="JIT099F5">5</xref>). The magnitude of the total response was similar
in survivors and nonsurvivors, but IFN-Î³âproducing and TNF-Î±âproducing
CRAG-specific CD4<sup>+</sup> T-cell counts tended to be higher in survivors than
nonsurvivors (24 cells/mL vs 9 cells/mL [<italic>P</italic> = .26] and 41 cells/mL
vs 11 cells/mL [<italic>P</italic> = .09]). <fig id="JIT099F5" position="float"><label>Figure
5.</label><caption><p>The absolute cryptococcal antigen (CRAG)âspecific
cytokineâproducing, interferon Î³ (IFN-Î³)âproducing, tumor
necrosis factor Î± (TNF-Î±)âproducing and macrophage inflammatory
protein 1Î± (MIP-1Î±)âproducing CD4<sup>+</sup> T-cell counts at
baseline in subjects who survived and subjects who died. Absolute numbers of
antigen-specific CD4<sup>+</sup> T cells were calculated by multiplying the
proportion of cytokine-positive CD4<sup>+</sup> T cells by the total
CD4<sup>+</sup> T-cell count. Responses are shown according to 2-week
mortality outcome. Statistical comparisons were made using the MannâWhitney
<italic>U</italic> test.</p></caption><graphic xlink:href="jit09905"/></fig></p>
                <p>Given this dichotomous association, patients were then analyzed according to whether they
had an IFN-Î³â and/or TNF-Î±âproducing CRAG-specific T-cell response at
baseline (hereafter referred to as âIFN-Î³/TNF-Î± responseâ). Twenty
patients (45%) had detectable IFN-Î³â and/or TNF-Î±âproducing
CRAG-specific CD4<sup>+</sup> T-cell responses. Overall, patients with an
IFN-Î³/TNF-Î± response were significantly more likely to survive than those without
this response (2-week mortality, 0% [0 patients] vs 25% [6 patients];
<italic>P</italic> = .025). Even in an analysis restricted to patients with a
CRAG-specific total response at baseline, with responses split into
MIP-1Î±âpredominant responses (&gt;50% MIP-1Î± producing) or
IFN-Î³/TNF-Î±âpredominant responses (&lt;50% MIP-1Î± producing),
those with the IFN-Î³/TNF-Î±âpredominant response had lower mortality at 2
weeks (0% vs 19%; <italic>P</italic> = .16), significantly lower
baseline fungal burdens (10 400 colony-forming units [CFU]/mL vs 390 000 CFU/mL;
<italic>P</italic> &lt; .001) and more rapid clearance of cryptococcal infection from
the CSF (early fungicidal activity, â0.64 vs â0.52 log<sub>10</sub>
CFU/mL/day; <italic>P</italic> = .16).</p>
              </sec>
              <sec id="s3e">
                <title>Correlations Between CRAG-Specific CD4<sup>+</sup> T-Cell Responses and the CSF
Immune Response</title>
                <p>We examined relationships between CRAG-specific CD4<sup>+</sup> T-cell responses and
12 CSF immune parameters (CSF lymphocyte count and IL-2, IL-4, IL-6, IL-10, IL-17,
IFN-Î³, TNF-Î±, RANTES, MIP-1Î±, MCP-1, and GM-CSF concentrations). Absolute
CRAG-specific CD4<sup>+</sup> T-cell counts (total response and IFN-Î³â,
TNF-Î±â, and MIP-1Î±âproducing cells) were correlated with CSF
lymphocyte counts and log<sub>10</sub> CSF cytokine/chemokine concentrations, using the
Spearman correlation coefficient. The total CRAG-specific CD4<sup>+</sup> T-cell
count was not significantly correlated with the CSF lymphocyte count or any of the
cytokines or chemokines. However, as with the clinical associations, it appeared that the
<italic>phenotype</italic>, rather than the <italic>magnitude</italic> of the peripheral
T-cell response, was most relevant. The IFN-Î³âproducing CRAG-specific
CD4<sup>+</sup> T-cell count was significantly associated with an increasing CSF
lymphocyte count (Spearman rho, 0.34; <italic>P</italic> = .02), and a similar
although nonsignificant association was found between the TNF-Î±âproducing
CRAG-specific CD4<sup>+</sup> T-cell count and an increasing CSF lymphocyte count
(Spearman rho, 0.26; <italic>P</italic> = .09). IFN-Î³â and
TNF-Î±âproducing CRAG-specific CD4<sup>+</sup> T-cell counts were also
positively associated with CSF IL-10 and IL-17 concentrations (Spearman rho, 0.29 for
IFN-Î³ and IL-10 [<italic>P</italic> = .05], 0.27 for TNF-Î± and IL-10
[<italic>P</italic> = .08], 0.21 for IFN-Î³ and IL-17 [<italic>P</italic>
= .2], and 0.42 for TNF-Î± and IL-17 [<italic>P</italic> = .005]) and
negatively associated with MCP-1 concentrations (Spearman rho, â0.35 for IFN-Î³
and MCP-1 [<italic>P</italic> = .02] and â0.27 for TNF-Î± and MCP-1
[<italic>P</italic> = .08]).</p>
                <p>To examine the influence of CD4<sup>+</sup> T-cell response phenotype independently
from magnitude, an analysis restricted to patients with a CRAG-specific total response at
baseline was performed, with responses classified as MIP-1Î± predominant or
IFN-Î³/TNF-Î± predominant as described above. Patients with
IFN-Î³/TNF-Î±âpredominant CRAG-specific CD4<sup>+</sup> T-cell responses
had higher levels of proinflammatory cytokines in the CSF and lower levels of MIP-1Î±,
MCP-1, and GM-CSF (Figure <xref ref-type="fig" rid="JIT099F6">6</xref>). <fig id="JIT099F6" position="float"><label>Figure 6.</label><caption><p>Cerebrospinal fluid (CSF) immune parameters in subjects with and subjects
without an interferon Î³ (IFN-Î³)/tumor necrosis factor Î±
(TNF-Î±)âpredominant cryptococcal antigen (CRAG)âspecific
CD4<sup>+</sup> T-cell response. CSF cytokine concentrations in patients with
a detectable CRAG-specific CD4<sup>+</sup> memory T-cell response are shown,
divided into patients with an IFN-Î³/TNF-Î±âpredominant response or a
macrophage inflammatory protein 1Î± (MIP-1Î±)âpredominant response. A
detectable total CD4<sup>+</sup> T-cell response was defined as at least
0.1% of cells cytokine positive after subtraction of background, with at
least 10 cytokine-positive events over background. A MIP-1Î±âpredominant
response was defined as &gt;50% of CRAG-specific cells producing MIP-1Î±,
and a IFN-Î³/TNF-Î±âpredominant response was defined as &lt;50%
CRAG-specific cells producing MIP-1Î±. Statistical comparisons were made using
the MannâWhitney <italic>U</italic> test. Abbreviations: GM-CSF,
granulocyte-macrophage colony-stimulating factor; MCP-1, monocyte chemotactic
protein 1.</p></caption><graphic xlink:href="jit09906"/></fig></p>
              </sec>
              <sec id="s3f">
                <title>Effects of Exogenous Interferon Gamma on Systemic Immune Responses</title>
                <p>The 44 patients in this study are a subset of a 90-patient cohort enrolled in a clinical
trial assessing the effect of adjuvant interferon gamma administration on the rate of
clearance of cryptococcal infection from the CSF of patients with HIV-associated
cryptococcal meningitis. Administration of interferon gamma with standard antifungal
therapy led to significantly faster rates of clearance of infection than standard therapy
alone [<xref ref-type="bibr" rid="JIT099C42">42</xref>]. When examined according to
baseline antigen-specific CD4<sup>+</sup> T-cell responses, the effects of adjunctive
interferon gamma therapy were found to be most marked in patients who had no CRAG-specific
IFN-Î³/TNF-Î±âproducing CD4<sup>+</sup> T-cell response at baseline. In
the 24 patients without an IFN-Î³/TNF-Î±âproducing CD4<sup>+</sup> T-cell
response at baseline, the addition of interferon gamma led to an increase of 0.25
log<sub>10</sub> CFU/mL/day (95% confidence interval [CI], .07â.43) in the
rate of clearance (<italic>P</italic> = .01), compared with an increase of 0.15
log<sub>10</sub> CFU/mL/day (95% CI, â.05â.35) in the rate among
those with a CRAG-specific IFN-Î³/TNF-Î±âproducing CD4<sup>+</sup> T-cell
response (<italic>P</italic> = .14), following adjustment for absolute
CD4<sup>+</sup> T-cell count and baseline fungal burden.</p>
                <p>To determine whether administration of adjuvant interferon gamma had an effect on the
CRAG-specific T-cell response, the change in magnitude of the total CRAG-specific
CD4<sup>+</sup> T-cell response over the initial 2 weeks of antifungal treatment
was examined with respect to interferon gamma exposure. Overall, interferon gamma
treatment was not found to have a statistically significant impact on either the change in
magnitude of the total CRAG-specific response between days 1 and 14 or the phenotype of
the CD4<sup>+</sup> T-cell response on day 14 (<ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jit099/-/DC1">Supplementary Figure 1</ext-link><italic>A</italic>). Interferon gammaâtreated
patients had proportionally less single-function MIP-1Î±âproducing
CD4<sup>+</sup> T cells than controls on day 14 (24% vs 67%) and
higher percentages of single-positive IFN-Î³â and TNF-Î±âproducing cells
(4% vs 1% and 13% vs 4%, respectively) and dual-function
IFN-Î³/TNF-Î±âproducing cells (11% vs 6%).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>DISCUSSION</title>
              <p>This is the first study characterizing antigen-specific peripheral CD4<sup>+</sup>
T-cell responses to <italic>Cryptococcus</italic> in patients with HIV-associated
cryptococcal meningitis. Although this work is primarily a descriptive, or
âdiscovery,â study examining a relatively small and heterogeneous patient
population, clear trends are evident when the results are taken as a whole, providing novel
data and unique insights. The magnitude of CRAG-specific CD4<sup>+</sup> T-cell
responses in patients with active cryptococcal infection was similar to the magnitude of
CMV-specific and <italic>M. tuberculosis</italic>âspecific responses, even though none
of these patients had clinically apparent CMV disease and only one-third had evidence of
active tuberculosis. CRAG-specific CD4<sup>+</sup> T-cell responses differed markedly
from <italic>M. tuberculosis</italic>âspecific and CMV-specific responses in terms of
maturational and functional profiles. <italic>M. tuberculosis</italic>âspecific
CD4<sup>+</sup> T cells were the least differentiated and were primarily TNF-Î±
producing. CMV-specific CD4<sup>+</sup> T cells exhibited a highly differentiated
effector-memory phenotype, primarily produced IFN-Î³ and TNF-Î±, and included large
numbers of polyfunctional cells. CRAG-specific CD4<sup>+</sup> T cells had a more
differentiated maturational profile than <italic>M. tuberculosis</italic>âspecific
CD4<sup>+</sup> cells but were less differentiated than CMV-specific cells. A large
proportion of CRAG-specific cells produced MIP-1Î±, with slightly lower proportions
producing IFN-Î³ or TNF-Î±, and very little polyfunctionality observed. Following ART
initiation, CRAG-specific responses decreased or remained constant, in keeping with a
reduction in antigen burden during effective antifungal therapy. In contrast, the magnitude
of both <italic>M. tuberculosis</italic>â and CMV-specific responses increased
following ART initiation, particularly markedly in the case of <italic>M.
tuberculosis</italic>âspecific responses. From low levels of <italic>M.
tuberculosis</italic>âspecific IFN-Î³ production at baseline (when TNF-Î±
predominated), there was a 10-fold increase in the frequency of IFN-Î³âproducing
CD4<sup>+</sup> T cells after 1 month of ART. This observation is consistent with the
observed poor performance of IFN-Î³ release assays in the diagnosis of tuberculosis in
highly immune-suppressed populations [<xref ref-type="bibr" rid="JIT099C47">47</xref>].</p>
              <p>Although CD4<sup>+</sup> T-cell depletion is the key predisposing factor for
development of HIV-associated cryptococcal meningitis, in this cohort of patients with
cryptococcal meningitis the functional phenotype of the CRAG-specific CD4<sup>+</sup>
T-cell response was associated with disease severity and clinical outcome, unlike the
overall magnitude of response. Survivors had higher proportions of IFN-Î³â and
TNF-Î±âproducing cells and significantly lower proportions of
MIP-1Î±âproducing cells. When analyzed according to the presence or absence of an
IFN-Î³/TNF-Î±âproducing CRAG-specific CD4<sup>+</sup> T-cell response,
those with such a response were found to have higher CSF lymphocyte counts, a more
proinflammatory CSF cytokine response, significantly lower baseline fungal burdens, a trend
to more rapid clearance of infection from the CSF, and a significantly lower 2-week
mortality.</p>
              <p>No Th2- or Th17-type antigen-specific cytokine production was seen in response to
mannoprotein stimulation. Given the widely reported role of Th2-type responses in animal
models of cryptococcal meningitis [<xref ref-type="bibr" rid="JIT099C16">16</xref>, <xref ref-type="bibr" rid="JIT099C22">22</xref>, <xref ref-type="bibr" rid="JIT099C23">23</xref>, <xref ref-type="bibr" rid="JIT099C28">28</xref>], and especially in light of the
described Th2-weighting of immune responses in late-stage HIV-infection [<xref ref-type="bibr" rid="JIT099C37">37</xref>], this may seem surprising. However this finding
could be related to the use of mannoprotein rather than whole-organism or other capsular
components in cell stimulations. Cryptococcal mannoproteins have previously been shown to
elicit delayed-type hypersensitivity and Th1-type cytokines [<xref ref-type="bibr" rid="JIT099C48">48</xref>, <xref ref-type="bibr" rid="JIT099C49">49</xref>], while other
capsular components, notably GXM, appear to inhibit these responses, promoting detrimental
Th2-type immunity [<xref ref-type="bibr" rid="JIT099C50">50</xref>]. It is possible that,
rather than Th2-type CD4<sup>+</sup> T-cell responses to <italic>C.
neoformans</italic>, an absolute lack of CD4<sup>+</sup> T cells may lead to
detrimental Th2-type cytokine production by monocytes/macrophages or glial cells in
HIV-associated cryptococcal meningitis. However, we found no inverse correlation between
either total or IFN-Î³/TNF-Î±âproducing CRAG-specific peripheral
CD4<sup>+</sup> T-cell counts and Th2-type CSF cytokine levels. The only inverse
correlation seen was between the number of IFN-Î³/TNF-Î±âproducing CRAG-specific
peripheral CD4<sup>+</sup> T cells and the chemokine MCP-1, suggesting that an adequate
peripheral CD4<sup>+</sup> T-cell response leads to downregulation of CNS chemokine
production.</p>
              <p>In terms of determining the mechanism by which exogenous IFN-Î³ leads to more rapid
clearance of cryptococcal infection from the CSF, our results are inconclusive. The benefits
of exogenous IFN-Î³ were most marked in patients with no
IFN-Î³/TNF-Î±âproducing CRAG-specific peripheral CD4<sup>+</sup> T-cell
response. However, this did not reach statistical significance, possibly because our study
was underpowered for such comparisons, particularly for subgroup analyses and in situations
where there was much heterogeneity of responses. As the biological effects of exogenous
IFN-Î³ may primarily result from direct activation of innate effector cells such as
monocytes/macrophages and microglial cells, a limitation of this study is that innate
effector-cell function was not directly examined. Further work is required to better
characterize the subgroup of patients who have poor baseline immune responses to
<italic>Cryptococcus</italic>, in whom adjuvant immunotherapy may be of most benefit.</p>
              <p>In conclusion, the presence of an IFN-Î³/TNF-Î±âproducing CRAG-specific
peripheral CD4<sup>+</sup> T-cell response has been shown to correlate with favorable
microbiological and clinical outcomes in patients with HIV-associated cryptococcal
meningitis. Mannoprotein stimulation of peripheral CD4<sup>+</sup> T cells did not lead
to Th2-cytokine production even in these patients with advanced HIV. Unlike animal models,
we found no evidence of a dichotomous Th1/Th2 response in this cohort of patients with
advanced HIV infection and cryptococcal meningitis. Rather, an
IFN-Î³/TNF-Î±âproducing CRAG-specific peripheral CD4<sup>+</sup> T-cell
response was associated with increased concentrations of cytokines at the site of infection,
including classical Th1 cytokines, as well as IL-10 and IL-17, and the presence of this
combined inflammatory response appears to be beneficial, while its absence is
detrimental.</p>
            </sec>
            <sec sec-type="supplementary-material" id="s5">
              <title>Supplementary Data</title>
              <p><ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/lookup/suppl/doi:10.1093/infdis/jit099/-/DC1">Supplementary materials</ext-link> are available at <italic>The Journal of Infectious
Diseases</italic> online (<uri xlink:type="simple" xlink:href="http://jid.oxfordjournals.org/">http://jid.oxfordjournals.org/</uri>). Supplementary materials consist of data provided
by the author that are published to benefit the reader. The posted materials are not
copyedited. The contents of all supplementary data are the sole responsibility of the
authors. Questions or messages regarding errors should be addressed to the author.</p>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Supplementary Data</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="supp_207_12_1817__index.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_jit099_jit099supp.doc"/>
                <media xlink:role="associated-file" mimetype="image" mime-subtype="jpeg" xlink:href="supp_jit099_jit099supp_fig1.jpg"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Notes</title>
              <p><bold><italic>Acknowledgments.</italic></bold>âWe thank Chrono Lee, for technical
assistance purifying the cryptococcal mannoprotein; Nonzwaki Bangani, for assistance with
PBMC isolation and storage; G. Ntombomzi Williams, for providing clinical care to the
patients; and Robert J. Wilkinson, for providing laboratory assistance in Cape Town.</p>
              <p><bold><italic>Financial support.</italic></bold>âThis work was supported by
<funding-source>the Wellcome Trust</funding-source> (training fellowship
<award-id>WT081794</award-id> to J. N. J.) and <funding-source>the National Institutes of
Health</funding-source> (grant <award-id>RO1 AI025780</award-id> to S. M. L.). Flow
cytometry was supported by funding from <funding-source>the Intramural Research Program of
the Vaccine Research Center, National Institutes of Allergy and Infectious Disease,
National Institutes of Health</funding-source>. S. D. L. is funded by <funding-source>the
Wellcome Trust</funding-source> (grant <award-id>088590</award-id>).</p>
              <p><bold><italic>Potential conflicts of interest.</italic></bold>âAll authors: No
reported conflicts.</p>
              <p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of
Interest. Conflicts that the editors consider relevant to the content of the manuscript have
been disclosed.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="JIT099C1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Park</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Wannemuehler</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Marston</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Govender</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Pappas</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Chiller</surname>
                      <given-names>TM</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimation of the current global burden of cryptococcal meningitis among
persons living with HIV/AIDS</article-title>
                  <source>AIDS</source>
                  <year>2009</year>
                  <volume>23</volume>
                  <fpage>525</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="pmid">19182676</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Casadevall</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Steenbergen</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Nosanchuk</surname>
                      <given-names>JD</given-names>
                    </name>
                  </person-group>
                  <article-title>âReady madeâ virulence and âdual useâ virulence
factors in pathogenic environmental fungiâthe <italic>Cryptococcus
neoformans</italic> paradigm</article-title>
                  <source>Curr Opin Microbiol</source>
                  <year>2003</year>
                  <volume>6</volume>
                  <fpage>332</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="pmid">12941400</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Yates</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Lipscomb</surname>
                      <given-names>MF</given-names>
                    </name>
                  </person-group>
                  <article-title>Immunity to a pulmonary <italic>Cryptococcus neoformans</italic> infection
requires both CD4+ and CD8+ T cells</article-title>
                  <source>J Exp Med</source>
                  <year>1991</year>
                  <volume>173</volume>
                  <fpage>793</fpage>
                  <lpage>800</lpage>
                  <pub-id pub-id-type="pmid">1672543</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Lipscomb</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Lovchik</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Hoag</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Street</surname>
                      <given-names>NE</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of CD4+ and CD8+ T cells in the protective inflammatory
response to a pulmonary cryptococcal infection</article-title>
                  <source>J Leukoc Biol</source>
                  <year>1994</year>
                  <volume>55</volume>
                  <fpage>35</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="pmid">7904293</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hill</surname>
                      <given-names>JO</given-names>
                    </name>
                    <name>
                      <surname>Aguirre</surname>
                      <given-names>KM</given-names>
                    </name>
                  </person-group>
                  <article-title>CD4+ T cell-dependent acquired state of immunity that protects the
brain against <italic>Cryptococcus neoformans</italic></article-title>
                  <source>J Immunol</source>
                  <year>1994</year>
                  <volume>152</volume>
                  <fpage>2344</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="pmid">7907637</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buchanan</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Doyle</surname>
                      <given-names>HA</given-names>
                    </name>
                  </person-group>
                  <article-title>Requirement for CD4(+) T lymphocytes in host resistance against
<italic>Cryptococcus neoformans</italic> in the central nervous system of immunized
mice</article-title>
                  <source>Infect Immun</source>
                  <year>2000</year>
                  <volume>68</volume>
                  <fpage>456</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="pmid">10639404</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoag</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Lipscomb</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Izzo</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Street</surname>
                      <given-names>NE</given-names>
                    </name>
                  </person-group>
                  <article-title>IL-12 and IFN-gamma are required for initiating the protective Th1 response
to pulmonary cryptococcosis in resistant C.B-17 mice</article-title>
                  <source>Am J Respir Cell Mol Biol</source>
                  <year>1997</year>
                  <volume>17</volume>
                  <fpage>733</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="pmid">9409560</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wozniak</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Ravi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Macias</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Insights into the mechanisms of protective immunity against
<italic>Cryptococcus neoformans</italic> infection using a mouse model of pulmonary
cryptococcosis</article-title>
                  <source>PLoS One</source>
                  <year>2009</year>
                  <volume>4</volume>
                  <fpage>e6854</fpage>
                  <pub-id pub-id-type="pmid">19727388</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kawakami</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kohno</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kadota</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>T cell-dependent activation of macrophages and enhancement of their
phagocytic activity in the lungs of mice inoculated with heat-killed
<italic>Cryptococcus neoformans</italic>: involvement of IFN-gamma and its protective
effect against cryptococcal infection</article-title>
                  <source>Microbiol Immunol</source>
                  <year>1995</year>
                  <volume>39</volume>
                  <fpage>135</fpage>
                  <lpage>43</lpage>
                  <pub-id pub-id-type="pmid">7783686</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C10">
                <label>10</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Milam</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Herring-Palmer</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Pandrangi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>McDonald</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Toews</surname>
                      <given-names>GB</given-names>
                    </name>
                  </person-group>
                  <article-title>Modulation of the pulmonary type 2 T-cell response to <italic>Cryptococcus
neoformans</italic> by intratracheal delivery of a tumor necrosis factor
alpha-expressing adenoviral vector</article-title>
                  <source>Infect Immun</source>
                  <year>2007</year>
                  <volume>75</volume>
                  <fpage>4951</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="pmid">17646355</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wormley</surname>
                      <given-names>FL</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                    <name>
                      <surname>Perfect</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Steele</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>GM</given-names>
                    </name>
                  </person-group>
                  <article-title>Protection against cryptococcosis by using a murine gamma
interferon-producing Cryptococcus neoformans strain</article-title>
                  <source>Infect Immun</source>
                  <year>2007</year>
                  <volume>75</volume>
                  <fpage>1453</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="pmid">17210668</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herring</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>McDonald</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Toews</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                  </person-group>
                  <article-title>Induction of interleukin-12 and gamma interferon requires tumor necrosis
factor alpha for protective T1-cell-mediated immunity to pulmonary <italic>Cryptococcus
neoformans</italic> infection</article-title>
                  <source>Infect Immun</source>
                  <year>2002</year>
                  <volume>70</volume>
                  <fpage>2959</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="pmid">12010985</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kawakami</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tohyama</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Teruya</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kudeken</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Xie</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Saito</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Contribution of interferon-gamma in protecting mice during pulmonary and
disseminated infection with <italic>Cryptococcus neoformans</italic></article-title>
                  <source>FEMS Immunol Med Microbiol</source>
                  <year>1996</year>
                  <volume>13</volume>
                  <fpage>123</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="pmid">8731020</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Toews</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Burdick</surname>
                      <given-names>MD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Afferent phase production of TNF-alpha is required for the development of
protective T cell immunity to <italic>Cryptococcus neoformans</italic></article-title>
                  <source>J Immunol</source>
                  <year>1996</year>
                  <volume>157</volume>
                  <fpage>4529</fpage>
                  <lpage>36</lpage>
                  <pub-id pub-id-type="pmid">8906831</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C15">
                <label>15</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kawakami</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Qureshi</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Interferon-gamma (IFN-gamma)-dependent protection and synthesis of
chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice
infected with <italic>Cryptococcus neoformans</italic></article-title>
                  <source>Clin Exp Immunol</source>
                  <year>1999</year>
                  <volume>117</volume>
                  <fpage>113</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="pmid">10403924</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arora</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Olszewski</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Tsang</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>McDonald</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Toews</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of cytokine interplay on macrophage polarization during chronic
pulmonary infection with <italic>Cryptococcus neoformans</italic></article-title>
                  <source>Infect Immun</source>
                  <year>2011</year>
                  <volume>79</volume>
                  <issue>5</issue>
                  <fpage>1915</fpage>
                  <lpage>25</lpage>
                  <pub-id pub-id-type="pmid">21383052</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Qiu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Dayrit</surname>
                      <given-names>JK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Immune modulation mediated by cryptococcal laccase promotes pulmonary
growth and brain dissemination of virulent <italic>Cryptococcus neoformans</italic> in
mice</article-title>
                  <source>PLoS One</source>
                  <year>2012</year>
                  <volume>7</volume>
                  <fpage>e47853</fpage>
                  <pub-id pub-id-type="pmid">23110112</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hardison</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Herrera</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Young</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Hole</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Wozniak</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Wormley</surname>
                      <given-names>FL</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <article-title>Protective immunity against pulmonary cryptococcosis is associated with
STAT1-Mediated classical macrophage activation</article-title>
                  <source>J Immunol</source>
                  <year>2012</year>
                  <volume>189</volume>
                  <fpage>4060</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="pmid">22984078</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C19">
                <label>19</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>He</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Lyons</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Toffaletti</surname>
                      <given-names>DL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Virulence factors identified by <italic>Cryptococcus neoformans</italic>
mutant screen differentially modulate lung immune responses and brain
dissemination</article-title>
                  <source>Am J Pathol</source>
                  <year>2012</year>
                  <volume>181</volume>
                  <fpage>1356</fpage>
                  <lpage>66</lpage>
                  <pub-id pub-id-type="pmid">22846723</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C20">
                <label>20</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wozniak</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Hardison</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Olszewski</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wormley</surname>
                      <given-names>FL</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <article-title>Induction of protective immunity against cryptococcosis</article-title>
                  <source>Mycopathologia</source>
                  <year>2012</year>
                  <volume>173</volume>
                  <fpage>387</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="pmid">22143898</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C21">
                <label>21</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Decken</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kohler</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Palmer-Lehmann</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Interleukin-12 is essential for a protective Th1 response in mice infected
with <italic>Cryptococcus neoformans</italic></article-title>
                  <source>Infect Immun</source>
                  <year>1998</year>
                  <volume>66</volume>
                  <fpage>4994</fpage>
                  <lpage>5000</lpage>
                  <pub-id pub-id-type="pmid">9746609</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C22">
                <label>22</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koguchi</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kawakami</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Cryptococcal infection and Th1-Th2 cytokine balance</article-title>
                  <source>Int Rev Immunol</source>
                  <year>2002</year>
                  <volume>21</volume>
                  <fpage>423</fpage>
                  <lpage>38</lpage>
                  <pub-id pub-id-type="pmid">12486822</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C23">
                <label>23</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blackstock</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Buchanan</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Adesina</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>JW</given-names>
                    </name>
                  </person-group>
                  <article-title>Differential regulation of immune responses by highly and weakly virulent
<italic>Cryptococcus neoformans</italic> isolates</article-title>
                  <source>Infect Immun</source>
                  <year>1999</year>
                  <volume>67</volume>
                  <fpage>3601</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="pmid">10377145</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C24">
                <label>24</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Muller</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Stenzel</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Kohler</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IL-13 induces disease-promoting type 2 cytokines, alternatively activated
macrophages and allergic inflammation during pulmonary infection of mice with
<italic>Cryptococcus neoformans</italic></article-title>
                  <source>J Immunol</source>
                  <year>2007</year>
                  <volume>179</volume>
                  <fpage>5367</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="pmid">17911623</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C25">
                <label>25</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blackstock</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>JW</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of interleukin-4 in resistance to <italic>Cryptococcus
neoformans</italic> infection</article-title>
                  <source>Am J Respir Cell Mol Biol</source>
                  <year>2004</year>
                  <volume>30</volume>
                  <fpage>109</fpage>
                  <lpage>17</lpage>
                  <pub-id pub-id-type="pmid">12855407</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C26">
                <label>26</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huffnagle</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>GH</given-names>
                    </name>
                    <name>
                      <surname>Curtis</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>McDonald</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Strieter</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Toews</surname>
                      <given-names>GB</given-names>
                    </name>
                  </person-group>
                  <article-title>Down-regulation of the afferent phase of T cell-mediated pulmonary
inflammation and immunity by a high melanin-producing strain of <italic>Cryptococcus
neoformans</italic></article-title>
                  <source>J Immunol</source>
                  <year>1995</year>
                  <volume>155</volume>
                  <fpage>3507</fpage>
                  <lpage>16</lpage>
                  <pub-id pub-id-type="pmid">7561046</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C27">
                <label>27</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Almeida</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Andrade</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Bento</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>The capsular polysaccharides of <italic>Cryptococcus neoformans</italic>
activate normal CD4(+) T cells in a dominant Th2 pattern</article-title>
                  <source>J Immunol</source>
                  <year>2001</year>
                  <volume>167</volume>
                  <fpage>5845</fpage>
                  <lpage>51</lpage>
                  <pub-id pub-id-type="pmid">11698459</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C28">
                <label>28</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Muller</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Piehler</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Stenzel</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Lack of IL-4 receptor expression on T helper cells reduces T helper 2 cell
polyfunctionality and confers resistance in allergic bronchopulmonary
mycosis</article-title>
                  <source>Mucosal Immunol</source>
                  <year>2012</year>
                  <volume>5</volume>
                  <fpage>299</fpage>
                  <lpage>310</lpage>
                  <pub-id pub-id-type="pmid">22333910</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C29">
                <label>29</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Tompkins</surname>
                      <given-names>KC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Robust Th1 and Th17 immunity supports pulmonary clearance but cannot
prevent systemic dissemination of highly virulent <italic>Cryptococcus
neoformans</italic> H99</article-title>
                  <source>Am J Pathol</source>
                  <year>2009</year>
                  <volume>175</volume>
                  <fpage>2489</fpage>
                  <lpage>500</lpage>
                  <pub-id pub-id-type="pmid">19893050</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C30">
                <label>30</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kleinschek</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Muller</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Brodie</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IL-23 enhances the inflammatory cell response in <italic>Cryptococcus
neoformans</italic> infection and induces a cytokine pattern distinct from
IL-12</article-title>
                  <source>J Immunol</source>
                  <year>2006</year>
                  <volume>176</volume>
                  <fpage>1098</fpage>
                  <lpage>106</lpage>
                  <pub-id pub-id-type="pmid">16393998</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C31">
                <label>31</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Szymczak</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Sellers</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Pirofski</surname>
                      <given-names>LA</given-names>
                    </name>
                  </person-group>
                  <article-title>IL-23 dampens the allergic response to <italic>Cryptococcus
neoformans</italic> through IL-17-independent and -dependent
mechanisms</article-title>
                  <source>Am J Pathol</source>
                  <year>2012</year>
                  <volume>180</volume>
                  <fpage>1547</fpage>
                  <lpage>59</lpage>
                  <pub-id pub-id-type="pmid">22342846</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C32">
                <label>32</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wozniak</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Hardison</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Kolls</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Wormley</surname>
                      <given-names>FL</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of IL-17A on resolution of pulmonary C. neoformans
infection</article-title>
                  <source>PLoS One</source>
                  <year>2011</year>
                  <volume>6</volume>
                  <fpage>e17204</fpage>
                  <pub-id pub-id-type="pmid">21359196</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C33">
                <label>33</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jarvis</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>TS</given-names>
                    </name>
                  </person-group>
                  <article-title>HIV-associated cryptococcal meningitis</article-title>
                  <source>AIDS</source>
                  <year>2007</year>
                  <volume>21</volume>
                  <fpage>2119</fpage>
                  <lpage>29</lpage>
                  <pub-id pub-id-type="pmid">18090038</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C34">
                <label>34</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bicanic</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Muzoora</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Brouwer</surname>
                      <given-names>AE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Independent association between rate of clearance of infection and clinical
outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262
patients</article-title>
                  <source>Clin Infect Dis</source>
                  <year>2009</year>
                  <volume>49</volume>
                  <fpage>702</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="pmid">19613840</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C35">
                <label>35</label>
                <element-citation publication-type="confproc">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bicanic</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Jarvis</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Loyse</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Determinants of acute outcome and long-term survival in HIV-associated
cryptococcal meningitis: results from a combined cohort of 523 patients [abstract
P-123]</article-title>
                  <conf-name>18th Conference on Retroviruses and Opportunistic Infections</conf-name>
                  <conf-loc>Boston, MA</conf-loc>
                  <comment>27 Februaryâ2 March 2011.</comment>
                </element-citation>
              </ref>
              <ref id="JIT099C36">
                <label>36</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Siddiqui</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Brouwer</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Wuthiekanun</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IFN-gamma at the site of infection determines rate of clearance of
infection in cryptococcal meningitis</article-title>
                  <source>J Immunol</source>
                  <year>2005</year>
                  <volume>174</volume>
                  <fpage>1746</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="pmid">15661940</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C37">
                <label>37</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Altfeld</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Addo</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Kreuzer</surname>
                      <given-names>KA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected
patients is detectable by reverse transcriptase polymerase chain reaction but not by
enzyme-linked immunosorbent assay under nonstimulated conditions</article-title>
                  <source>J Acquir Immune Defic Syndr</source>
                  <year>2000</year>
                  <volume>23</volume>
                  <fpage>287</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="pmid">10836750</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C38">
                <label>38</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gong</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Iyer</surname>
                      <given-names>DV</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Modlin</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Barnes</surname>
                      <given-names>PF</given-names>
                    </name>
                  </person-group>
                  <article-title>T cell cytokine responses in persons with tuberculosis and human
immunodeficiency virus infection</article-title>
                  <source>J Clin Invest</source>
                  <year>1994</year>
                  <volume>94</volume>
                  <fpage>2435</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="pmid">7989601</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C39">
                <label>39</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Clerici</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Shearer</surname>
                      <given-names>GM</given-names>
                    </name>
                  </person-group>
                  <article-title>A TH1â&gt;TH2 switch is a critical step in the etiology of HIV
infection</article-title>
                  <source>Immunol Today</source>
                  <year>1993</year>
                  <volume>14</volume>
                  <fpage>107</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="pmid">8096699</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C40">
                <label>40</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Geldmacher</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ngwenyama</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Schuetz</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Preferential infection and depletion of <italic>Mycobacterium
tuberculosis</italic>-specific CD4 T cells after HIV-1 infection</article-title>
                  <source>J Exp Med</source>
                  <year>2010</year>
                  <volume>207</volume>
                  <fpage>2869</fpage>
                  <lpage>81</lpage>
                  <pub-id pub-id-type="pmid">21115690</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C41">
                <label>41</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Casazza</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Brenchley</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Autocrine production of beta-chemokines protects CMV-specific CD4 T cells
from HIV infection</article-title>
                  <source>PLoS Pathog</source>
                  <year>2009</year>
                  <volume>5</volume>
                  <fpage>e1000646</fpage>
                  <pub-id pub-id-type="pmid">19876388</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C42">
                <label>42</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jarvis</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Meintjes</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Rebe</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Adjunctive interferon-gamma immunotherapy for the treatment of
HIV-associated cryptococcal meningitis: a randomized controlled trial</article-title>
                  <source>AIDS</source>
                  <year>2012</year>
                  <volume>26</volume>
                  <fpage>1105</fpage>
                  <lpage>13</lpage>
                  <pub-id pub-id-type="pmid">22421244</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C43">
                <label>43</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wozniak</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Levitz</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Isolation and purification of antigenic components of
Cryptococcus</article-title>
                  <source>Methods Mol Biol</source>
                  <year>2009</year>
                  <volume>470</volume>
                  <fpage>71</fpage>
                  <lpage>83</lpage>
                  <pub-id pub-id-type="pmid">19089377</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C44">
                <label>44</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Betts</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Nason</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>West</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>HIV nonprogressors preferentially maintain highly functional HIV-specific
CD8+ T cells</article-title>
                  <source>Blood</source>
                  <year>2006</year>
                  <volume>107</volume>
                  <fpage>4781</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="pmid">16467198</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C45">
                <label>45</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roederer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nozzi</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Nason</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>SPICE: exploration and analysis of post-cytometric complex multivariate
datasets</article-title>
                  <source>Cytometry A</source>
                  <year>2011</year>
                  <volume>79</volume>
                  <fpage>167</fpage>
                  <lpage>74</lpage>
                  <pub-id pub-id-type="pmid">21265010</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C46">
                <label>46</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brenchley</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Karandikar</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Betts</surname>
                      <given-names>MR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Expression of CD57 defines replicative senescence and antigen-induced
apoptotic death of CD8+ T cells</article-title>
                  <source>Blood</source>
                  <year>2003</year>
                  <volume>101</volume>
                  <fpage>2711</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="pmid">12433688</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C47">
                <label>47</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Metcalfe</surname>
                      <given-names>JZ</given-names>
                    </name>
                    <name>
                      <surname>Everett</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>Steingart</surname>
                      <given-names>KR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Interferon-gamma release assays for active pulmonary tuberculosis diagnosis
in adults in low- and middle-income countries: systematic review and
meta-analysis</article-title>
                  <source>J Infect Dis</source>
                  <year>2011</year>
                  <volume>204</volume>
                  <issue>Suppl 4</issue>
                  <fpage>S1120</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="pmid">21996694</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C48">
                <label>48</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levitz</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Specht</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>The molecular basis for the immunogenicity of <italic>Cryptococcus
neoformans</italic> mannoproteins</article-title>
                  <source>FEMS Yeast Res</source>
                  <year>2006</year>
                  <volume>6</volume>
                  <fpage>513</fpage>
                  <lpage>24</lpage>
                  <pub-id pub-id-type="pmid">16696647</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C49">
                <label>49</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levitz</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>North</surname>
                      <given-names>EA</given-names>
                    </name>
                  </person-group>
                  <article-title>Lymphoproliferation and cytokine profiles in human peripheral blood
mononuclear cells stimulated by <italic>Cryptococcus neoformans</italic></article-title>
                  <source>J Med Vet Mycol</source>
                  <year>1997</year>
                  <volume>35</volume>
                  <fpage>229</fpage>
                  <lpage>36</lpage>
                  <pub-id pub-id-type="pmid">9292418</pub-id>
                </element-citation>
              </ref>
              <ref id="JIT099C50">
                <label>50</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yauch</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Levitz</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Direct inhibition of T-cell responses by the Cryptococcus capsular
polysaccharide glucuronoxylomannan</article-title>
                  <source>PLoS Pathog</source>
                  <year>2006</year>
                  <volume>2</volume>
                  <fpage>e120</fpage>
                  <pub-id pub-id-type="pmid">17096589</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
